Dapagliflozin plus Saxagliptin in Diabetic Patients with Renal Disease

In a manufacturer-sponsored trial, researchers examined whether the combination of dapagliflozin (a sodium-glucose cotransporter-2 inhibitor) and saxagliptin (a dipeptidyl peptidase-4 inhibitor) reduces proteinuria in patients with type 2 diabetes and chronic kidney disease. Nearly 500 such patients were randomized to a daily dose of dapagliflozin (10 mg) plus saxagliptin (2.5 mg), dapagliflozin alone (10 mg), or placebo. Enrollment criteria included urine albumin-to-creatinine ratio (UACR) of 30 to 3500 mg/g, glomerular filtration rate (GFR) of 25 to 75 mL/minute/1.73 m², and glycosylated hemoglobin (HbA_1c) of 7% to 11%. All patients already were taking angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, plus various…